Clinical Trials
306 trialsNCT05519085 2026-05-27
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT06158841 2026-05-27
CERVINO
AbbVie
Phase 3 Recruiting
NCT07095452 2026-05-27
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT07227311 2026-05-26
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT01946477 2026-05-22
POM MM 014
Celgene
Phase 2 Completed
NCT06152575 2026-05-22
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT07138209 2026-05-22
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06433947 2026-05-19
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Opna Bio LLC
Phase 1 Recruiting
NCT05623020 2026-05-14
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT06615479 2026-05-13
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07579234 2026-05-12
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD
Phase 3 Recruiting
NCT03934684 2026-05-11
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT04181827 2026-05-11
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04973605 2026-05-11
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05669989 2026-05-11
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT05688475 2026-05-11
A Rollover Study of CC-122
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT04923893 2026-05-08
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05083169 2026-05-08
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05438043 2026-05-08
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05552222 2026-05-08
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06577025 2026-05-08
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT07569757 2026-05-08
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06413498 2026-05-07
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT04126200 2026-05-06
DREAMM 5
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT06106945 2026-05-06
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
Phase 1/2 Recruiting
NCT05020236 2026-05-05
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT03173092 2026-05-04
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
Phase 4 Terminated
NCT03319667 2026-05-04
IMROZ
Sanofi
Phase 3 Active not recruiting
NCT05583617 2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07391657 2026-04-30
DURGA-4
AstraZeneca
Phase 3 Recruiting
NCT05090566 2026-04-24
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Terminated
NCT04246047 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868654 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868667 2026-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06679101 2026-04-22
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT06163898 2026-04-21
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1 Terminated
NCT02719613 2026-04-15
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Completed
NCT04133636 2026-04-13
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03984097 2026-04-09
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Completed
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04756726 2026-03-25
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics, Inc.
Phase 1 Active not recruiting
NCT07452198 2026-03-25
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3 Recruiting